Cardiff Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Cardiff Oncology, Inc. on June 20, 2024. A total of 27,736,982 shares were represented, constituting a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Four proposals were submitted to stockholders. The results are as follows:
- Proposal 1 (Election of Directors): All seven nominees were elected. Votes ranged from approximately 15.2 million to 15.5 million "For" with zero "Against" votes.
- Proposal 2 (Ratification of Auditors): The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ended December 31, 2024, was approved with 27,146,093 "For" votes.
- Proposal 3 (Equity Plan Amendment): An amendment to increase the number of shares issuable under the 2021 Equity Incentive Plan to 8,150,000 shares was approved with 13,081,695 "For" votes.
- Proposal 4 (Say-on-Pay): The advisory vote on executive compensation was approved with 13,280,919 "For" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the amended 2021 Equity Incentive Plan (8,150,000 shares).
- Confirm the tenure of the newly elected directors, which extends until the 2025 Annual Meeting.
- Note the significant number of broker non-votes (approx. 11.9 million) on Proposals 1, 3, and 4, indicating shares held by brokers that were not voted on these specific matters.
- Review the Definitive Proxy Statement filed on April 25, 2024, for detailed background on the proposals.